Armistice Capital and Steven Boyd Reveal 9.79% Stake in Treace Medical Concepts
Armistice Capital, LLC and Steven Boyd have disclosed a 9.79% beneficial ownership stake in Treace Medical Concepts, Inc., totaling 6,364,000 shares. This stake, reported via a Schedule 13G filing on November 16, 2026, reflects shared voting and dispositive authority, with Armistice Capital Master Fund Ltd. as the direct holder. The acquisition is stated to be in the ordinary course of business and not intended to influence company control.
A passive stake of 6,364,000 shares is reported in Treace Medical Concepts (TMCI).
Armistice Capital, LLC and Steven Boyd have reported a passive stake of 6,364,000 common shares, representing 9.79% of Treace Medical Concepts, Inc. (TMCI). This disclosure was made in a Schedule 13G filing with the SEC, with the event date noted as September 30, 2026. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, its managing member, share voting and dispositive power over these shares.
Two beneficial owners report 6.36M Treace Medical (TMCI) shares in a passive stake amendment.
Armistice Capital, LLC and its managing member, Steven Boyd, have reported a passive stake of 6,364,000 shares in Treace Medical Concepts, Inc. (TMCI), representing 1.96% of the common stock as of September 30, 2026. This disclosure was made via a SCHEDULE 13G/A amendment, indicating shared voting and dispositive power over the shares, which are held directly by Armistice Capital Master Fund Ltd. The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.
Treace Medical Concepts upgraded by Stifel with a new price target
Stifel has upgraded Treace Medical Concepts (TMCI) from a "Hold" to a "Buy" rating, setting a new price target of $6.50. This bullish outlook was disseminated to Quantisnow Plus members immediately upon publication. The report also provides historical context on how TMCI's stock has traded following previous headlines.
What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings Call
Treace Medical Concepts (TMCI) reported a 4% decline in Q3 revenue due to a shift towards lower-priced products, despite growth in procedure volumes. The company narrowed its full-year revenue outlook but anticipates a return to growth in Q4, driven by higher procedure volumes and new product contributions. TMCI is expanding its product portfolio, increasing surgeon adoption, and expects to modestly expand its direct sales channel.
Treace Medical Concepts Q3 Revenue Falls 3.8% to $48.3 Million
Treace Medical Concepts (TMCI) reported a 3.8% decline in third-quarter 2026 revenue to $48.3 million, though this was slightly above estimates. The company's GAAP loss was 19 cents per share, which was better than analyst expectations, and its net loss improved by 23% to $12.6 million.
Treace Medical Concepts, Inc. (TMCI) Debt 2025: $55.6M, up 4.3%
Treace Medical Concepts, Inc. (TMCI) reported $55.6 million in long-term debt by the end of fiscal year 2025, an increase of 4.3% from the previous year, against $10.7 million in cash and equivalents. The article provides a detailed breakdown of TMCI's annual and quarterly debt and cash figures from 2019 through Q3 2026, highlighting growth trends and offering definitions of long-term debt.
Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction System
Treace Medical Concepts, Inc. has announced the successful completion of the first surgical cases using its new Tailorplasty™ MIS Tailor’s Bunion Correction System. This system is designed to correct painful deformities of the fifth metatarsal, known as tailor's bunions or "bunionettes," through a minimally invasive approach. The company estimates this new solution represents a $300M market expansion opportunity and anticipates commercialization in the first quarter of 2027.
Treace Medical Concepts Q3 2026 Earnings Call Transcript
Treace Medical Concepts reported a 4% revenue decrease in Q3 2026 to $48.3 million, primarily due to a shift towards lower-priced products, but expects a return to growth in Q4 with new product introductions and double-digit case volume growth. The company is expanding its product portfolio, including new bunion and foot/ankle systems, to increase its total addressable market by approximately $700 million. Management highlighted strong adoption of new products by existing Lapiplasty surgeons and the importance of clinical evidence, while reiterating full-year 2026 revenue guidance of $206-$210 million and expecting improved adjusted EBITDA.
Form 8K Treace Medical Concepts Inc For: 6 November By Investing.com
This article announces the filing of a Form 8K by Treace Medical Concepts Inc. on November 6. It also notes that the company's stock symbol is TMCI and mentions a -3.59% change, though no other details about the filing are provided.
Bunion procedure volume grew by double digits at Treace, even as revenue fell 4%.
Treace Medical Concepts reported a 4% decline in third-quarter 2026 revenue to $48.3 million, primarily due to a shift to lower-priced minimally invasive products and fewer bunion procedure kits sold. Despite this, the company achieved double-digit bunion procedure volume growth and narrowed its net loss to $12.6 million. Treace also updated its full-year 2026 financial outlook, narrowing its revenue guidance and reducing its expected adjusted EBITDA loss.
Treace Medical Concepts Reports Third Quarter 2026 Financial Results
Treace Medical Concepts reported its third-quarter 2026 financial results, with revenue of $48.3 million, a 4% decrease year-over-year, mainly due to a shift to lower-priced minimally invasive products. Despite the revenue decline, the company improved its net loss by 23% to $(12.6) million and Adjusted EBITDA to $0.3 million, driven by double-digit procedure volume growth and targeted expense reductions. Treace also updated its full-year 2026 revenue guidance to $206 million to $210 million and expects a reduced Adjusted EBITDA loss of $1.0 million to $2.0 million.
Treace Medical Concepts, Inc. (TMCI) Tops Q3 EPS by 6c
Treace Medical Concepts, Inc. (TMCI) announced its Q3 earnings, reporting an EPS of ($0.19), which was $0.06 better than the analyst estimate of ($0.25). The company's revenue for the quarter reached $48.3 million, surpassing the consensus estimate of $47.71 million.
Form 8K Treace Medical Concepts Inc For: 6 November By Investing.com
This article announces that Treace Medical Concepts Inc. (TMCI) filed a Form 8K on November 6, 2026. The 8K filing is a report that companies must file with the SEC to announce major events that shareholders should know about. No specific details about the content of the 8K are provided in this brief announcement.
Treace to Present at the Stifel 2026 Healthcare Conference
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced it will present at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026, at approximately 1:20 pm ET. A live webcast and replay of the fireside chat will be accessible on the company's investor relations website. Treace is a medical technology company specializing in surgical treatments for bunions and other foot & ankle conditions, offering innovative systems like Lapiplasty® 3D Bunion Correction®.
A live webcast and replay will be available for Treace's Nov. 11 conference talk.
Treace Medical Concepts (TMCI) announced it will present at the Stifel 2026 Healthcare Conference on November 11, 2026, at approximately 1:20 pm ET. A live webcast and replay of the fireside chat will be accessible on the company’s investor relations website. The announcement, originally made on November 3, 2026, also highlights Treace's focus on surgical treatments for bunions and other foot & ankle conditions.
Treace Medical Concepts (TMCI) Expected to Post Quarterly Earnings on Friday
Treace Medical Concepts (TMCI) is anticipated to announce its Q3 2026 earnings before the market opens on Friday, November 6th. Analysts are forecasting a loss of $0.26 per share and revenue of $47.80 million. The company exceeded expectations in its previous quarter, reporting a smaller loss and higher revenue than projected, while TMCI shares recently traded up 4.8% at $5.06.
Treace Medical Faces Its Mix-Shift Lapping Test As Volume Gains Must Finally Reach Revenue
Treace Medical Concepts (TMCI) is facing a critical test in its September-quarter report, where rising case volumes and new bunion systems are expected to finally translate into healthier revenue trends after a period of shrinking sales. Analysts anticipate a narrower decline in revenue, suggesting the pricing drag from minimally invasive products is fading, but the operating details, particularly sustained high single-digit volume growth and continued adoption of new systems, will be crucial in validating the company's turnaround narrative. The stock's recent performance suggests much of the recovery story is already priced in, making the third-quarter results pivotal for future market sentiment.
Form 4 Treace Medical Concepts Inc: Sean F. Scanlan (Chief Innovation Officer) For: 24 October
This article reports on a Form 4 filing for Treace Medical Concepts Inc., detailing an insider transaction by Sean F. Scanlan, the Chief Innovation Officer. The filing pertains to activity on October 24. The article provides the company's stock symbol (TMCI) and its current performance.
After disposing of 207 shares, Treace Medical (TMCI) innovation chief Scanlan reports holding 634,656 shares.
Treace Medical Concepts, Inc.'s Chief Innovation Officer, Sean F. Scanlan, reported the disposition of 207 common shares on October 24, 2026, for tax liability. Following this transaction, his direct holdings total 634,656 shares, which include 462,317 restricted stock units. The reported amount also reflects a transfer of 45,000 common shares to his former spouse due to a domestic relations order.
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced it will release its third-quarter 2026 financial results on Friday, November 6, 2026, before the market opens. The company will host a conference call at 8:00 am ET to discuss the results, with registration required for participation. A webcast of the event will also be available on their investor relations website.
Treace Medical Concepts, Inc. Estimates – NASDAQ:TMCI
This page on TradingView provides financial data and analyst estimates for Treace Medical Concepts, Inc. (NASDAQ: TMCI). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, and compare actual results with average, high, and low estimates, visualizing trends over time. The platform explicitly states that the information provided is not investment advice and encourages users to conduct their own research.
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced it will release its third-quarter 2026 financial results on Friday, November 6, 2026, before market open. Company management will host a conference call at 8:00 AM ET to discuss these results, with details for registration available for investors. A webcast of the event will also be accessible on the Company's investor relations website.
Treace Medical Wilts Ahead of Q3 Figures
Treace Medical Concepts, Inc. (NASDAQ:TMCI) shares fell on Friday ahead of the release of its third-quarter 2026 financial results. The medical technology company, which focuses on surgical treatments for bunions, plans to announce its figures before market open on Friday, November 6, followed by a conference call. Shares of TMCI dropped 4.5% to $4.09.
A company focused on bunion surgery will discuss third-quarter results at 8 a.m. ET Nov. 6.
Treace Medical Concepts (TMCI) will release its third-quarter 2026 financial results before trading opens on November 6, 2026. Management will host a conference call at 8:00 am ET to discuss these results, with a live and archived webcast available on the company's investor relations website. Treace is a medical technology company specializing in surgical treatments for bunions and related midfoot deformities.
Treace Medical Concepts Q3 2026 Earnings Date and Estimates
Treace Medical Concepts (TMCI) is projected to announce its Q3 2026 earnings on Thursday, November 5, 2026, before the market opens, with a conference call scheduled for 4:30 PM ET. Analysts anticipate the company will report -$0.26 earnings per share on revenue of $47.80 million, representing a 4.8% decrease in revenue year-over-year. The company has a history of beating EPS consensus estimates in 6 out of its last 8 quarters.
25,457 shares were delivered or withheld at Treace Medical (TMCI), leaving 753,226 directly held.
Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary at Treace Medical Concepts, Inc. (TMCI), had 25,457 shares delivered or withheld on September 30, 2026, for tax liability or exercise price payment. Following this transaction, his direct holdings in the company totaled 753,226 shares, which include 524,030 restricted stock units. This transaction was reported in a Form 4 SEC filing.
Form 4 Treace Medical Concepts Inc For: 2 October By Investing.com
This article announces the filing of Form 4 for Treace Medical Concepts Inc. on October 2nd, as reported by Investing.com. It is a brief, informative post indicating a regulatory filing has occurred for the company. The article contains minimal descriptive text beyond the headline.
Form 4 Treace Medical Concepts Inc For: 2 October By Investing.com
This article reports on a Form 4 filing for Treace Medical Concepts Inc. for October 2nd. The content primarily consists of the title repeated several times, along with a link to Investing.com's financial markets platform.
Treace Medical Concepts Inc (TMCI-Q) Stock Price and News
This page provides stock price and news updates for Treace Medical Concepts Inc (TMCI-Q). It includes real-time stock data, historical performance charts, dividend information, analyst ratings, financial reports, and a feed of recent news articles related to the company, highlighting earnings calls, product launches, and analyst recommendations. The company is described as a commercial-stage orthopedic medical device firm focused on treating Hallux Valgus.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Consensus Target Price of $5.17 According to Brokerages
Seven research firms have given Treace Medical Concepts (NASDAQ:TMCI) a consensus "Reduce" rating with an average 12-month price target of $5.17, which is higher than its current share price of $4.62. The company recently reported better-than-expected quarterly results but remains unprofitable, with analysts expecting a full-year loss. CEO John Treace and institutional investors have increased their holdings in the company.
Bank of America Corp DE Acquires 3,305,100 Shares of Treace Medical Concepts, Inc. $TMCI
Bank of America Corp DE has acquired a significant new stake of 3.31 million shares in Treace Medical Concepts, Inc. (NASDAQ:TMCI), valued at approximately $13.15 million, representing a 5.08% ownership. This move comes as institutional investors collectively own a substantial portion of the company, and insiders have also been increasing their holdings. Despite recent positive quarterly revenue and EPS, analysts maintain a cautious "Reduce" rating for TMCI.
Investigation launched into Treace Medical officers for possible breach of shareholder duties
Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of Treace Medical Concepts, Inc. The investigation encourages long-term shareholders to seek corporate reforms or financial relief, emphasizing the limited time to act. This initiative aims to protect investor interests and improve company governance, with a market snapshot showing mixed performance in the health sector.
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Treace Medical Concepts, Inc. (NASDAQ: TMCI) breached their fiduciary duties to shareholders. The firm encourages current long-term shareholders to contact them to discuss their legal rights and options, which may include seeking corporate governance reforms or the return of funds to the company.
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLP, an investor rights law firm, is investigating whether certain officers and directors of Treace Medical Concepts, Inc. (NASDAQ: TMCI) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss legal rights and options, which may include corporate governance reforms, return of funds, or other relief. Shareholder involvement is emphasized as a way to improve company transparency and value.
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
Treace Medical (NASDAQ: TMCI) has announced five-year ALIGN3D results for its Lapiplasty bunion-correction procedure, showing durable outcomes in a study with 137 of 173 original patients. While the evidence supports sustained alignment and patient improvement, the lack of a comparison group and missing patient data for the final analysis limit its conclusiveness. The commercial success will depend on whether this data can drive broader surgeon adoption and translate into improved revenue and margins for the company.
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
Treace Medical Concepts (TMCI) announced five-year results for its Lapiplasty bunion-correction procedure, showing a low radiographic recurrence rate of 0.8% (for cases greater than 20 degrees) and clinically meaningful improvements in patient outcomes. While this long-term data strengthens the case for Lapiplasty's durability, challenges remain in proving superiority over competing procedures and translating clinical evidence into increased revenue and profitability for the company.
96.6% of patients showed healing after foot surgery
Treace Medical Concepts (TMCI) announced positive results from three clinical studies for its Lapiplasty®, Adductoplasty®, and SpeedPlate® technologies, presented at the 2026 AOFAS Annual Meeting. Key findings include sustained outcomes for Lapiplasty over five years with low recurrence, early weight-bearing and maintained corrections for Adductoplasty, and high healing rates (96.6%) for SpeedPlate. These studies demonstrate the durability and clinical value of Treace's surgical solutions for bunions and other foot conditions.
Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting
Treace Medical Concepts announced the presentation of positive results from three clinical studies at the AOFAS Annual Meeting, highlighting the effectiveness of their bunion and foot condition treatments. The studies demonstrated low recurrence rates, early weight-bearing, and significant improvements in patient-reported outcomes for their ALIGN3D®, MTA3D®, and SPRINT™ procedures. These findings reinforce Treace's commitment to innovation and improving surgical outcomes for patients.
Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting
Treace Medical Concepts announced the presentation of results from three clinical studies at the AOFAS Annual Meeting in Seattle, highlighting the effectiveness of their bunion and foot condition surgical procedures. The studies, including a 5-year follow-up on ALIGN3D®, 2-year interim results for MTA3D®, and a 1-year SPRINT™ study, demonstrated significant early weight-bearing, low recurrence rates, high union rates, and positive patient-reported outcomes. These findings reinforce Treace's commitment to innovative technologies and improved surgical outcomes for foot ailments.
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
Treace Medical Concepts, Inc. is showcasing new product innovations and presenting clinical data at the 2026 AOFAS Annual Meeting. The company is expanding its portfolio in foot and ankle conditions, featuring advancements in 3D bunion correction systems like the Lapiplasty® Lightning™ System, and new entries into the mid and hindfoot markets with products such as SuperBite™ Fully-Threaded Compression Screws and HyperPlate™ XM. Clinical data from landmark studies (ALIGN3D®, MTA3D®, SPRINT™) will also be presented, highlighting the performance of Treace technologies.
Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026
Treace Medical Concepts, Inc. will participate in the American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle from September 16-19, 2026. The company plans to introduce new products for bunion treatment and broader midfoot and hindfoot applications, including the Lapiplasty® Lightning™ System and Tailorplasty™ MIS Tailor’s Bunion System. Additionally, Treace will present clinical data from significant studies on its ALIGN3D® Lapiplasty®, MTA3D® Adductoplasty®, and SPRINT™ SpeedPlate® technologies.
New bunion tools and five-year study results will be shown in Seattle
Treace Medical Concepts will showcase new product innovations and present clinical data at the 2026 AOFAS Annual Meeting in Seattle. The company will highlight advancements in its 3D bunion correction portfolio, including new instrumentation and a minimally invasive tailor's bunion system, along with new offerings for midfoot and hindfoot markets. Clinical results from 5-year ALIGN3D® Lapiplasty®, MTA3D® Adductoplasty®, and SPRINT™ SpeedPlate® studies will also be presented.
BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI
BlackRock Inc. has acquired a new position of 1.38 million shares, valued at $5.5 million, in Treace Medical Concepts (NASDAQ:TMCI) during the second quarter. Other institutional investors also increased their stakes in the company, with institutional ownership now at 84.08%. Despite beating revenue and EPS estimates in its latest earnings report, Treace Medical Concepts remains unprofitable, and analysts currently have a "Reduce" rating on the stock with an average price target of $5.17.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts
Analysts have issued a consensus "Reduce" rating for Treace Medical Concepts (NASDAQ:TMCI), with an average 12-month price target of $5.17. Despite the company exceeding quarterly revenue and EPS estimates, it remains unprofitable with a negative net margin. Notably, insiders, including the CEO, have recently purchased over 108,000 shares.
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 39,944 Shares of Stock
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace purchased 39,944 shares of the company's stock on August 20th for $4.44 per share, totaling approximately $177,351. Following this acquisition, Treace now owns 7.39 million shares. The company recently reported better-than-expected quarterly revenue of $45.38 million and an adjusted loss of $0.24 per share, surpassing analyst estimates.
John Treace Acquires 5,000 Shares of Treace Medical Concepts (NASDAQ:TMCI) Stock
CEO John Treace recently acquired 5,000 shares of Treace Medical Concepts (NASDAQ:TMCI) for $21,750, increasing his total holdings to 7.39 million shares. The company's latest quarterly results surpassed revenue and EPS expectations, despite a cautious "Reduce" rating from analysts and an average price target of $5.17. Institutional investors hold a significant 84.08% stake in the medical technology firm.
Insider Buying: Treace Medical Concepts (NASDAQ:TMCI) CEO Acquires 11,000 Shares
Treace Medical Concepts CEO John Treace recently purchased 11,000 shares of the company's stock for $47,740, increasing his direct ownership to over 7.4 million shares. Despite the CEO's increased stake and the company beating Q2 analyst estimates for revenue and EPS, institutional investors own a significant portion of the company. However, analyst sentiment remains cautious, with an average "Reduce" rating and a consensus price target of $5.17.
Treace Medical (TMCI) CEO adds to stake with late‑August buys
John T. Treace, CEO and director of Treace Medical Concepts, Inc. (TMCI), purchased 55,944 shares of common stock in late August 2026 through open-market transactions. These purchases were made on August 20, 21, and 24, at weighted average prices between $4.34 and $4.44 per share, and were not conducted under a Rule 10b5-1 trading plan. The filing also detailed significant indirect holdings attributed to his spouse and various trusts, for which Mr. Treace disclaims beneficial ownership.
Weber Capital Management LLC ADV Takes $2.35 Billion Position in Treace Medical Concepts, Inc. $TMCI
Weber Capital Management LLC ADV has acquired a new stake of 589,617 shares, valued at approximately $2.35 billion, in Treace Medical Concepts, Inc. This position represents 0.91% of the company and 2.0% of Weber Capital Management's portfolio. Despite cautious analyst sentiment with a "Reduce" rating, Treace Medical Concepts reported a smaller-than-expected quarterly loss and higher-than-anticipated revenue, while institutional investors collectively own 84.08% of the company's stock.